Aurora Cannabis, Bitdeer Technologies Group, and other big stocks move lower in pre-market session.

Aurora Cannabis shares fell 20.1% to $4.70 in pre-market trading after posting a quarterly loss of 24 cents per share. Other big stocks moving lower include Cerro Therapeutics Holdings, Regencell Bioscience Holdings, Vince Holding Corp, Jyong Biotech, Bitdeer Technologies Group, and Fresenius Medical Care AG.

Title: Aurora Cannabis Reports Narrowing Loss, Adjusted EBITDA Surges; Stocks Fall Pre-Market

Aurora Cannabis Inc. (ACB, ACB.TO), a leading Canadian medical cannabis company, reported a narrower net loss in its fourth quarter, with adjusted EBITDA surging significantly. The company's net loss from continuing operations was $17.23 million, a 14.7% improvement over the prior year's $20.327 million. Adjusted EBITDA increased by 619% to $16.68 million, up from $2.32 million a year ago. Total net revenue was $90.5 million, up 34% from $67.4 million in the prior year period.

The growth was primarily driven by a 48% increase in global medical cannabis business and a 32% growth in plant propagation business, which were partially offset by a 20% decrease in consumer cannabis net revenue. Medical cannabis net revenue increased due to higher sales in Australia, Germany, Poland, and the UK, as well as increased revenue from insurance-covered and self-paying patients in Canada.

Aurora's stock, trading on the Nasdaq, fell by 10.5% in pre-market activity, trading at $5.26. The company expects continued strong global cannabis revenue in the first quarter, driven by improved performance in Canadian medical and comparable performance in consumer cannabis, offset by temporary declines in some international markets. However, adjusted EBITDA is expected to decline sequentially in the first quarter due to lower revenue contributions from higher margin international markets.

Other notable movements in the pre-market trading session include Cerro Therapeutics Holdings, which saw its stock more than double after receiving FDA orphan drug designation for its lead drug candidate for acute myeloid leukemia [2]. Regencell Bioscience Holdings, Vince Holding Corp, Jyong Biotech, Bitdeer Technologies Group, and Fresenius Medical Care AG also experienced significant declines.

References:
1. [Aurora Cannabis Q4 Loss Narrows, Adj. EBITDA Surges](https://www.nasdaq.com/articles/aurora-cannabis-q4-loss-narrows-adjebitda-surges-sees-sequentially-weak-demand-q1-stock)
2. [Cero Therapeutics Holdings Jumps After Leukemia Treatment Gets FDA Orphan Drug Designation](https://www.marketwatch.com/story/cero-therapeutics-holdings-jumps-after-leukemia-treatment-gets-fda-orphan-drug-designation-0ccf72a1)